Search Result

Results for "

DOX

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Adrenergic Receptor (5) Aldose Reductase (1) AMPK (1) Antibiotic (1) Apoptosis (6) Autophagy (3) Bacterial (1) Carbonic Anhydrase (1) Endogenous Metabolite (2) ERK (2) Ferroptosis (2) HBV (1) Histone Methyltransferase (1) HIV (1) Isotope-Labeled Compounds (2) Keap1-Nrf2 (2) mGluR (1) Mitophagy (1) MMP (2) P-glycoprotein (4) PROTAC Linkers (1) Reactive Oxygen Species (1) Topoisomerase (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (4) Infection (1) Metabolic Disease (1) Neurological Disease (1)

By Targets:

ADC Cytotoxin (1)

Adrenergic Receptor (5)

Aldose Reductase (1)

AMPK (1)

Antibiotic (1)

Apoptosis (6)

Autophagy (3)

Bacterial (1)

Carbonic Anhydrase (1)

Endogenous Metabolite (2)

ERK (2)

Ferroptosis (2)

HBV (1)

Histone Methyltransferase (1)

HIV (1)

Isotope-Labeled Compounds (2)

Keap1-Nrf2 (2)

mGluR (1)

Mitophagy (1)

MMP (2)

P-glycoprotein (4)

PROTAC Linkers (1)

Reactive Oxygen Species (1)

Topoisomerase (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (22)

Cardiovascular Disease (4)

Infection (1)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153797

Dox-btn2	ADC Cytotoxin Antibiotic Bacterial Topoisomerase AMPK HIV HBV Apoptosis Autophagy Mitophagy	Infection Cancer
Dox-btn2 is a biotinylated derivative of Doxorubicin (HY-15142A), with a biotin label at the point of conjugation to doxorubicin at 3'-NH₂. Dox-btn2 can be used for cell imaging. While Doxorubicin is mainly accumulated in the nucleus, while Dox-btn2 is mainly located in the cytoplasm .

HY-B0006B

(S)-Carvedilol (S)-BM 14190	Adrenergic Receptor	Cardiovascular Disease
(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX) .

HY-B0006C

(R)-Carvedilol (R)-BM 14190	Adrenergic Receptor	Cardiovascular Disease
(R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX) .

HY-125907

Dox-Ph-PEG1-Cl

PROTAC Linker 34
PROTAC Linkers Cancer

Dox-Ph-PEG1-Cl (PROTAC Linker 34) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs .
HY-163078

C2-Gal-Dox

Others Cancer

C2-Gal-Dox is a galactose conjugate with high cytotoxicity. C2-Gal-Dox inhibits the growth of a variety of cancer cells .

Dox-Ph-PEG1-Cl PROTAC Linker 34	PROTAC Linkers	Cancer
Dox-Ph-PEG1-Cl (PROTAC Linker 34) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs .

C2-Gal-Dox	Others	Cancer
C2-Gal-Dox is a galactose conjugate with high cytotoxicity. C2-Gal-Dox inhibits the growth of a variety of cancer cells .

HY-144825

Chol-CTPP	Apoptosis Reactive Oxygen Species	Cancer
Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP). Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function .

HY-N10642

Pedaliin 6''-acetate	Others	Others
Pedaliin 6''-acetate (compound 10) is a natural product that can be isolated from Dracocephalum tanguticum. Pedaliin 6''-acetate shows antioxidative activity and cytoprotective effect on doxorubicin (DOX)-induced toxicity in H9c2 cardiomyocytes with an EC₅₀ value of 19.1 μM .

HY-122182

OTS193320	Histone Methyltransferase Apoptosis	Cancer
OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (DOX; HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .

HY-144769

SDOX	Topoisomerase	Cancer
SDOX is the Doxorubicin (DOX) proagent. The loaded DOX proagents (SDOX) which can release the parent agents DOX triggered by excessive GSH in tumor cells, minimize the unexpected side effects on normal tissues without compromising the potency .

HY-157484

P-gp inhibitor 19	P-glycoprotein	Cancer
P-gp inhibitor 19 (Compound 6i) is a P-gp inhibitor. P-gp inhibitor 19 can inhibit the efflux of rhodamine 123 (HY-D0816) in P-gp-overexpressing leukemia cells K562/Dox and also restore the sensitivity of DOX-resistant cells .

HY-155035

S07-1066	Others	Cancer
S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells .

HY-157483

P-gp inhibitor 18	P-glycoprotein	Cancer
P-gp inhibitor 18 (compound 6G) is a potent inhibitor of P-gp. P-gp inhibitor 18 inhibits rhodamine 123 efflux in the P-gp overexpressed leukemia cells, K562/Dox .

HY-B0006BS

(S)-Carvedilol-d4 (S)-BM 14190-d₄	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease
(S)-Carvedilol-d₄ is deuterium labeled (S)-Carvedilol. (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].

HY-B0006CS

(R)-Carvedilol-d4 (R)-BM 14190-d₄	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease
(R)-Carvedilol-d₄ is deuterium labeled (R)-Carvedilol. (R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].

HY-N11638

Ganoderic acid R	Apoptosis	Cancer
Ganoderic acid R is a potent anticancer agent. Ganoderic acid R inhibits the growth by inducing apoptosis on tumor cell line. Ganoderic acid R possesses significant cytotoxicity on a multidrug resistance (MDR) tumor cell line (KB-A-1/Dox) and a sensitive tumor cell line (KB-A-1) .

HY-N2591

Isocorydine	Endogenous Metabolite	Cancer
Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

HY-N2591A

Isocorydine hydrochloride	Endogenous Metabolite	Cancer
Isocorydine hydrochloride is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine hydrochloride combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .

HY-P2004

FFAGLDD	MMP	Cancer
FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

HY-P2004A

FFAGLDD TFA	MMP	Cancer
FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

HY-N10564

8α,9α-Epoxycoleon-U-quinone	P-glycoprotein	Cancer
8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits P-gp activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .

HY-100489

TBHQ 65+ Cited Publications tert-Butylhydroquinone	Keap1-Nrf2 ERK Autophagy Apoptosis Ferroptosis	Cancer
TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2 . TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma .

HY-163363

β-AR antagonist 2	Adrenergic Receptor	Cancer
β-AR antagonist 2 (compound 43) is an antagonist of β-AR (IC₅₀: 0.17 μM). β-AR-IN-1 inhibits the growth of mouse A549 xenograft tumors and shows cardioprotective efficacy against DOX-induced HF in C57 mice .

HY-100489R

TBHQ (Standard) tert-Butylhydroquinone (Standard)	Keap1-Nrf2 ERK Autophagy Apoptosis Ferroptosis	Cancer
TBHQ (Standard) is the analytical standard of TBHQ. This product is intended for research and analytical applications. TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2 . TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma .

HY-152188

AKR1C3-IN-9	Aldose Reductase	Cancer
AKR1C3-IN-9 is a selective inhibitor of Aldo-keto Reductase 1C3 (AKR1C3) with an IC₅₀ value of 8.92 nM. AKR1C3-IN-9 significantly reverses the Doxorubicin (HY-15142A) (DOX) resistance in a resistant breast cancer cell line .

HY-N6022

Byakangelicin	Others	Metabolic Disease
Byakangelicin, one of the active compounds found in the roots of Angelica gigas, can serve as a modulator to improve brain accumulation of diverse active compounds (Umb, Cur, and Dox) and enhance therapeutic effects . Byakangelicin is likely to increase the expression of all PXR target genes (such as MDR1) and induce a wide range of agent-agent interactions. Byakangelicin can inhibit the effects of sex hormones, it may increase the catabolism of endogenous hormones .

HY-150648

S07-2008

Others Cancer

S07-2008 is a selective aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC₅₀ of 0.16 μM. S07-2008 shows anticancer activities .

S07-2008	Others	Cancer
S07-2008 is a selective aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC₅₀ of 0.16 μM. S07-2008 shows anticancer activities .

HY-155391

hCA/Wnt/β-catenin-IN-1	Carbonic Anhydrase P-glycoprotein Wnt β-catenin	Cancer
hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (K_i: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .

HY-150644

S07-2010	Others	Cancer
S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC₅₀ values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells .

HY-110122

AZ 12216052 1 Publications Verification	mGluR	Neurological Disease
AZ 12216052 is a mGluR8 positive allosteric modulator, and helps mGluR8 modulate signaling inputing to retinal ganglion cells. AZ 12216052 exhibits antianxiety effect .

FFAGLDD	MMP	Cancer
FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

FFAGLDD TFA	MMP	Cancer
FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

Cat. No.	Product Name	Category	Target	Chemical Structure